2 months ago
Tisagenlecleucel CAR-T: A Breakthrough in Cancer Treatment Tisagenlecleucel, a groundbreaking cellular immunotherapy, has revolutionized the treatment of certain types of cancer. As a CAR T cell th...
2 months ago
Breaking Barriers: Equecabtagene Autoleucel Revives Hope for International RRMM Patients – Multiple Myeloma Multiple Myeloma Relapsed/refractory multiple myeloma (RRMM) presents a significant...
2 months ago
What are the indications for Tisagenlecleucel Approval The approval of tisagenlecleucel (Kymriah) by the U.S. Food and Drug Administration (FDA) marks a significant milestone in the field of cancer...
2 months ago
Celebrating Discharge: The Joy of a New Life/ Hope /Multiple myeloma After a period of treatment, the Singaporean patient Teresa achieved remarkable results with CAR-T therapy at Jiahui Internatio...
2 months ago
###庆祝出院：新生的喜悦 经过一段时间的治疗，新加坡患者Teresa在上海嘉会国际医院的CAR-T治疗取得了令人振奋的成果。她的病情完全达到了完全缓解（CR），在这一喜讯的见证下，医院为她举行了一场简短而温馨的...
2 months ago
Tecartus Yescarta Difference Chimeric Antigen Receptor T-cell (CAR-T) therapies have revolutionized the treatment landscape for certain types of cancer. Tecartus and Yescarta are two such groundbre...
2 months ago
**Groundbreaking Results for Chinese CAR-T Therapy: 86% Response Rate of BCMA/GPRC5D Dual-Target Treatment** Multiple myeloma #MultipleMyeloma #ChineseCART #BCMA #GPRC5D #DualTarget #MM #RRMM Mul...
2 months ago
Tecartus Target – CD19 Tecartus, a groundbreaking CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences, targets CD19, a protein expressed on the surface of certain blo...
2 months ago
Tecartus Price Tecartus comes with a substantial price of approximately $373,000 per treatment. Introduction Cancer treatment has come a long way, with advancements in technology and medical resear...
2 months ago
Redefining Hope for High-Risk RRMM Patients Worldwide: A Singaporean Patient`s Journey to China for Groundbreaking CAR-T Therapy Multiple Myeloma #MultipleMyeloma #CAR_Therapy #CancerTreatment #...
2 months ago
**Breaking Ground: The First Nectin-4 Targeted ADC Approved in China** Urothelial Carcinoma #UrothelialCarcinoma #Nectin4 #ADC On August 19, the National Medical Products Administration (NMPA) of...
2 months ago
Tecartus Mechanism of Action Tecartus, a CD19-directed genetically modified autologous T cell immunotherapy, has revolutionized the treatment landscape for relapsed or refractory mantle cell lympho...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
